Search research articles
Contact Us
Filters
Showing results (61-70 of 186) with videos related to
Page
of 19
Sort By:
Pediatric Diabetes
|
September 3, 2008
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial
Thomas Danne, Nicolin Datz, Lars Endahl, et al.
Pediatric Diabetes
|
April 20, 2020
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes
Torben Biester, Thekla von dem Berge, Line Quist Bendtsen, et al.
Pediatric Diabetes
|
August 31, 2012
Heterogeneity in the systems of pediatric diabetes care across the European Union
Ondrej Cinek, Zdeněk Sumník, Carine de Beaufort, et al.
Pediatric Diabetes
|
August 31, 2012
A pediatric diabetes toolbox for creating centres of reference
Karin Lange, Susan Klotmann, Heike Saßmann, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 4, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 27, 2020
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Technology & Therapeutics
|
February 10, 2021
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes
Peter Gerhardsson, Anke Schwandt, Michael Witsch, et al.
Journal of the Endocrine Society
|
June 30, 2025
A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults
Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 25, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
August 11, 2004
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis
Olga Kordonouri, Kathrin Meyer, Karl Egerer, et al.
Page
of 19
Search research articles
Search
Showing results (61-70 of 186) with videos related to
Sort By:
Page
of 19
Pediatric Diabetes
|
September 3, 2008
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial
Thomas Danne, Nicolin Datz, Lars Endahl, et al.
Pediatric Diabetes
|
April 20, 2020
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes
Torben Biester, Thekla von dem Berge, Line Quist Bendtsen, et al.
Pediatric Diabetes
|
August 31, 2012
Heterogeneity in the systems of pediatric diabetes care across the European Union
Ondrej Cinek, Zdeněk Sumník, Carine de Beaufort, et al.
Pediatric Diabetes
|
August 31, 2012
A pediatric diabetes toolbox for creating centres of reference
Karin Lange, Susan Klotmann, Heike Saßmann, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 4, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 27, 2020
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Technology & Therapeutics
|
February 10, 2021
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes
Peter Gerhardsson, Anke Schwandt, Michael Witsch, et al.
Journal of the Endocrine Society
|
June 30, 2025
A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults
Lori M Laffel, Thomas Danne, Georgeanna J Klingensmith, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 25, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
August 11, 2004
Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis
Olga Kordonouri, Kathrin Meyer, Karl Egerer, et al.
Page
of 19